ArticleCancer cell2019

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Christopher A Eide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.